DaVita, Inc. Hits New 52-Week High at USD 159.42

DaVita, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 159.42 on March 2, 2026. This achievement marks a notable increase from its 52-week low of USD 101, reflecting a year-over-year performance of 8.76%. The company's market capitalization stands at approximately USD 11,237 million, indicating its position within the small-cap category. DaVita's price-to-earnings (P/E) ratio is currently at 9.00, which provides insight into its valuation relative to earnings. However, the company has reported a negative return on equity of -163.56%, alongside a debt-to-equity ratio of -15.25, suggesting a complex financial structure. While the broader S&P 500 has outperformed DaVita with a return of 17.36% over the same period, the recent price movement highlights the stock's resilience and potential for growth within its industry. Investors and market observers will be keen to monitor how these dynamics evolve in the coming months.